(Q34334470)

1 August 2017

title

MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis (English)

1 reference

1 August 2017

1 reference

Jianwei Xu

1

1 reference

1 August 2017

Tianxiao Wang

2

1 reference

1 August 2017

Zhe Cao

3

1 reference

1 August 2017

Hua Huang

4

1 reference

1 August 2017

Jian Li

5

1 reference

1 August 2017

Wenjing Liu

6

1 reference

1 August 2017

Shanglong Liu

7

1 reference

1 August 2017

Lei You

8

1 reference

1 August 2017

Li Zhou

9

1 reference

1 August 2017

Taiping Zhang

10

1 reference

1 August 2017

Yupei Zhao

11

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

1 August 2017

1 reference

1 August 2017

volume

5

1 reference

1 August 2017

issue

16

1 reference

1 August 2017

page(s)

6983-6993

1 reference

miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

6 July 2018

Cancer statistics, 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Monoclonal antibodies and other targeted therapies for pancreatic cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Anticancer molecules targeting fibroblast growth factor receptors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Pancreatic cancer: understanding and overcoming chemoresistance

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Cellular signaling by fibroblast growth factor receptors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

AKT kinase pathway: a leading target in cancer research.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Loss of microRNA-200a expression correlates with tumor progression in breast cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196178

27 October 2018

Identifiers

DOI

10.18632/ONCOTARGET.2184

0 references

PMC publication ID

4196178

1 reference

1 August 2017

1 reference